XOMA Royalty (XOMA) Non Operating Investment Income (2024 - 2026)
XOMA Royalty's (XOMA) quarterly Non Operating Investment Income came in at $933000.0 in Q1 2026, up 0.65% year-on-year from $927000.0 in Q1 2025, and up 12.0% quarter-over-quarter from $833000.0 in Q4 2025.
XOMA Royalty (XOMA) Non Operating Investment Income (2024 - 2026) Analysis & Trends
XOMA Royalty has disclosed Non Operating Investment Income across 3 years of filings, most recently posting $933000.0 for Q1 2026.
- Non Operating Investment Income for Q1 2026 came in at $933000.0, up 0.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.5 million (down 39.16% YoY), and the FY2025 annual result was $3.5 million, down 46.56% from the prior year.
- Non Operating Investment Income came in at $933000.0 for Q1 2026 at XOMA Royalty, up from $833000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $1.7 million in Q3 2024 to a low of $833000.0 in Q4 2025.
- The 3-year median for Non Operating Investment Income is $930000.0 (2025), against an average of $1.1 million.
- Across the five-year window, Non Operating Investment Income plunged 49.88% in 2025 and gained 0.65% in 2026, its largest moves.
- XOMA Royalty's Non Operating Investment Income stood at $1.4 million in 2024, then slumped by 40.71% to $833000.0 in 2025, then advanced by 12.0% to $933000.0 in 2026.
- The last three Non Operating Investment Income figures came in at $933000.0 (Q1 2026), $833000.0 (Q4 2025), and $866000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 230,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | XOMA Royalty | 5.48 Mn | -60.60 Mn | - | 933,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 933,000.00 |
| Mar 31, 2026 | 933,000.00 |
| Dec 31, 2025 | 833,000.00 |
| Dec 31, 2025 | 833,000.00 |
| Sep 30, 2025 | 866,000.00 |
| Sep 30, 2025 | 866,000.00 |
| Jun 30, 2025 | 843,000.00 |
| Jun 30, 2025 | 843,000.00 |
| Mar 31, 2025 | 927,000.00 |
| Mar 31, 2025 | 927,000.00 |
| Dec 31, 2024 | 1.41 Mn |
| Dec 31, 2024 | 1.41 Mn |
| Sep 30, 2024 | 1.70 Mn |
| Sep 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.68 Mn |
| Jun 30, 2024 | 1.68 Mn |